Peptides in Alzheimer‘s Research

Drug Discovery and Development, Life Sciences, Preclinical,
  • June 22, 2016

Alzheimer‘s disease has become a major health and social problem in the developed countries with an increasing proportion of older people. Individuals suffering from this disease show a gradual loss of cognitive functions and disturbances in behavior. The onset of Alzheimer‘s disease is usually above 60 years and the risk to develop the disease increases with age.

In this webinar we present our amyloid peptides, inhibitors and labelled secretase substrates that are widely used in the research of Alzheimer’s disease. The deposition of amyloid β-peptide (Aβ) in the brain is characteristic for the disease and the resulting plaques mainly consist of Aβ (1-40) and Aβ (1-42). Despite the progresses in the understanding of the pathology of Alzheimer‘s disease, therapeutic strategies still rely on detailed knowledge of the molecules involved. Research covers the enzymatic processing of the amyloid precursor protein as well as the fate of the cleavage products.

Important enzymes include α, β- and γ-secretases, which cleave the amyloid precursor protein and define the composition of the resulting physiological peptides. Cleavage by β- and γ-secretases generates amyloid β-peptides. Inhibiting those enzymes has been suggested as a specific therapeutic intervention in preventing the progression of Alzheimer‘s disease. Cleavage products like amyloid β-peptides are e.g. used for in vitro aggregations studies.

Speakers

Violeta Jordan, Global Director of Product Management, Bachem

Violeta Jordan, Global Director of Product Management, Bachem

Violeta Jordan is a Global Director of Product Management for Bachem AG which is located in Bubendorf, Switzerland. Previously, for over 9 years she was a Global Director of Sales and Marketing at AnaSpec, located in Fremont, California. She joined AnaSpec from Winstar Communication and TestMart where she was a Sales Manager. Before these last 2 companies she worked at Zeneca, located in Richmond, California. This is many years before AstraZeneca and Syngenta were formed, where she worked as a Research Biologist or lab bench scientist. Violeta Jordan earned her M.B.A. from Golden Gate University in San Francisco, California and her B.S. in Chemistry and Agricultural Sciences from Kiril and Metodij, University of Macedonia.

Who Should Attend?

  • Research Associates, Research Scientists, Senior Scientists
  • Scientific Advisors
  • Heads/Directors of Research & Development
  • Heads/Directors of Peptide Discovery & Chemistry
  • Chemists
  • Biologists
  • Principal Investigators

Xtalks Partners

Bachem

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active Pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides.

Media Partners

Related Webinars

Sign Up To Register for this Webinar

Interested in this webinar? Signup to learn more and register for upcoming webinars or recorded webinars.

Sign Up